Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases

被引：0
|
作者：
Kavgaci, Akif [1 ]
Kula, Serdar [1 ]
Incedere, Fatma [1 ]
Terlemez, Semiha [1 ]
Tunaoglu, Fatma Sedef [1 ]
机构：
[1] Gazi Univ, Fac Med, Dept Pediat, Div Pediat Cardiol, Ankara, Turkiye
来源：
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 2023年 / 31卷 / 01期
关键词：
Pulmonary arterial hypertension; subcutaneous; treprostinil;
D O I：
10.5606/tgkdc.dergisi.2023.23748
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-related symptoms, or in cases where epoprostenol treatment should be reduced due to side effects. In this article, we describe three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.
引用
收藏
页码：145 / 148
页数：4
相关论文
共 50 条
  • [21] Three years experience with subcutaneous treprostinil therapy in severe pulmonary hypertension: clinic and haemodynamic assessment
    Jimenez, C.
    Escribano, P.
    Hernandez, F.
    Tello, R.
    Sadia, D.
    Delgado, J. F.
    Gomez-Sanchez, M. A.
    de la Calzada, C. S.
    EUROPEAN HEART JOURNAL, 2005, 26 : 80 - 80
  • [22] Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients
    Libri, V.
    Gibbs, J. S. R.
    Pinato, D. J.
    Iddamalgoda, T.
    Khengar, R. H.
    Gin-Sing, W.
    Huson, L.
    Anand, P.
    BRITISH JOURNAL OF ANAESTHESIA, 2014, 112 (02) : 337 - 347
  • [23] Gallbladder polyps in patients receiving subcutaneous treprostinil therapy for Pulmonary Arterial Hypertension.
    Cullivan, S.
    Boyle, N.
    Mc Cullagh, B.
    Gaine, S. P.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 1) : S34 - S35
  • [24] Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil
    Sadushi-Kolici, R.
    Shafran, I
    Skoro-Sajer, N.
    Campean, I-A
    Lang, I. M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2255 - 2255
  • [25] Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
    Barst, R. J.
    Galie, N.
    Naeije, R.
    Simonneau, G.
    Jeffs, R.
    Arneson, C.
    Rubin, L. J.
    EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) : 1195 - 1203
  • [26] Lowering of Mean Pulmonary Arterial Pressure is a Prognostic Marker in Pulmonary Hypertension Patients treated with Subcutaneous Treprostinil
    Sadushi-Kolici, Roela
    Shafran, Inbal
    Skoro-Sajer, Nika
    Gerges, Christian
    Lang, Irene
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [27] Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous Treprostinil
    Sadushi-Kolici, R.
    Shafran, I.
    Campean, I.
    Skoro-Sajer, N.
    Lang, I.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S286 - S286
  • [28] Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series
    Ackerbauer, Kimberly A.
    Tandon, Rajive
    JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 163 - 166
  • [29] USE OF INHALED TREPROSTINIL IN PULMONARY HYPERTENSION AND COPD
    Al-Bedour, Arwa
    Guice, Kenneth C.
    Sheikh, Muhammad M.
    CHEST, 2022, 162 (04) : 2411A - 2411A
  • [30] Treprostinil Decreases Platelet Microparticles in Pediatric Pulmonary Hypertension
    Bacha, Nour
    Levy, Marilyne
    Guerin, Coralie L.
    le Bonniec, Bernard
    Harroche, Annie
    Gaussem, Pascale
    Israel-Biet, Dominique
    Boulanger, Chantal M.
    Smadja, David M.
    CIRCULATION, 2017, 136
12345